Idera Pharmaceuticals, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Idera Pharmaceuticals, Inc., originally a biopharmaceutical enterprise, historically dedicated its efforts to advancing therapeutic compounds for various rare conditions within the United States. The company once concentrated on the development of Tilsotolimod (IMO-2125), a synthetic TLR9 agonist designed to activate immune responses against solid tumors, including squamous cell carcinoma of the head and neck and colorectal cancer. This former pipeline included a research collaboration with Bristol-Myers Squibb. However, Idera Pharmaceuticals, Inc. underwent a significant strategic transformation, culminating in its acquisition by Aceragen, Inc. in September 2022 and subsequent rebranding as Aceragen, Inc. in January 2023, with its stock ticker changing from IDRA to ACGN. The revitalized entity now focuses on pioneering treatments for orphan pulmonary and rheumatic disorders. Its current lead programs feature ACG-701, aimed at addressing acute pulmonary exacerbations in cystic fibrosis and melioidosis, and ACG-801, an enzyme replacement therapy under development for Farber disease. Established in 1989, the company maintains its operational base in Exton, Pennsylvania.
Energy Recovery Wins “Breakthrough Innovation Award” at IDRA World Congress
Buying Penny Stocks Right Now? 3 Top Tips to Know
3 Penny Stocks That Are Climbing During Today's Market Selloff
Why Are Idera Pharmaceuticals Shares Soaring Today
5 Top Biotech Penny Stocks Under $1 To Watch This Week
Hot Penny Stocks For 2022 To Buy For Under $2
5 Penny Stocks To Buy According To Analysts & Targets Up To 341%
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
IDRA Stock Price Increases Over 20% Pre-Market: Why It Happened
Idera Pharmaceuticals Announces Corporate Updates
Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
IDRA Stock Price Fell 62%: Why It Happened
Tomslist: The 5 Weirdest Penny Stock Stories of the Week
Why Idera Pharmaceuticals Stock Is Crashing Today
IDRA Stock Price Falls Over 60% Pre-Market: Why It Happened
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Idera acquires API developer Apilayer
Idera Pharmaceuticals to Present at Upcoming Conferences
Idera Pharmaceuticals (IDRA) in Focus: Stock Moves 9.4% Higher